The Biden Administration is preparing for a potential coronavirus surge this fall by purchasing millions of variant-specific COVID-19 booster shots. In addition to the 105 million doses already...
While the general public may feel we are post-pandemic, healthcare workers know that COVID still runs rampant worldwide, especially in hospital settings. The recent study published in JAMA Network Open...
Antivirals have rapidly become a popular topic with their implications in treating COVID-19. Understanding antivirals, their mechanisms, classes, and subtypes is an essential part of being able to treat viral infections such as the...
A cohort study in JAMA Network Open analyzed the efficacy of the COVID-19 vaccine in preventing SARS-CoV-2 reinfection. The study found that COVID-19 vaccination reduced reinfection rates by...
A post by the Commonwealth Fund approximates that over 100,000 lives would be saved with fall COVID booster campaigns. Though many people and institutions have the misconceived notion that the COVID...
In the year prior to the start of the coronavirus pandemic, 15.8% of American adults were using prescription medication to support their mental health; two years later, that number has risen to 23%,...
In May 2020, Phlow Corp. received $354 million to bring inexpensive generic pharmaceutical manufacturing to the United States. At the time, it was one of the largest coronavirus-era contracts to be...
The FDA Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0 in favor of recommending the Novavax coronavirus vaccine for emergency...
Late last month, Pfizer announced its coronavirus vaccine clinical trial results, indicating that a three-dose regimen of the Pfizer-BioNTech vaccine was safe and effective for children older than 6...
The National Institutes of Health (NIH) and the National Institutes of Allergy and Infectious Disease (NIAID)’s Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program...
On Tuesday, the CDC warned Americans about the potential for coronavirus recurrence after using Pfizer’s antiviral drug Paxlovid. CDC officials are not recommending any changes to the ordinary...
FDA recently amended the emergency use authorization for Pfizer and BioNTech’s COVID-19 vaccine booster to include individuals 5– 11 years of age at least five months after completing the...
FDA recently limited the authorized use of Johnson & Johnson's COVID-19 vaccine to include individuals 18 years of age and older for whom other authorized or approved vaccines are not...
Pfizer recently announced that its COVID-19 treatment, Paxlovid reduced disease by 32% and 37% in adults for 5–10 days, respectively, compared to placebo.
The Phase 2/3 EPIC-PEP study...
FDA recently expanded the approval for COVID-19 treatment, Veklury (remdesivir), to include pediatric patients 28 days of age and older weighing at least seven pounds.
The agency's decision...
FDA recently issued an emergency use authorization (EUA) for the first COVID-19 test that detects chemical compounds in breath samples associated with SARS-CoV-2 infection.
Qualified,...
The World Health Organization (WHO) recently updated the emergency use listing (EUL) for Johnson & Johnson’s COVID-19 vaccine, recommending it as a booster in individuals 18 years of age and...
FDA recently amended the emergency use authorization of Moderna's COVID-19 vaccine to allow for a second booster dose at the 50 microgram level in adults 50 years of age and older.
The...
Pfizer and BioNTech recently submitted an application to FDA for emergency use authorization (EUA) of an additional COVID-19 vaccine booster dose for adults 65 years and older.
The...
Novavax recently launched its global, unbranded vaccine programs, 'We Do Vaccines' and 'Know Our Vax' as educational efforts to help protect people's health in the fight against the...
